Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by MEI Pharma, Inc. on December 5, 2013. The filing covers the voting results for the fiscal year 2014. Note: The request metadata lists "Lite Strategy, Inc.", but the filing text explicitly identifies the registrant as MEI Pharma, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
Stockholders representing 14,377,505 shares (out of 17,117,152 outstanding) voted on three proposals:
- Proposal 1 (Election of Directors):
- Thomas C. Reynolds: Elected (12,833,450 For; 260,319 Withheld).
- William D. Rueckert: Not Elected (5,476,102 For; 7,617,667 Withheld).
- Christine A. White: Elected (12,817,169 For; 276,600 Withheld).
- Proposal 2 (Ratification of Auditors): Approved. BDO USA, LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2014 (14,314,208 For; 29,342 Against).
- Proposal 3 (Advisory Vote on Executive Compensation): Approved (8,127,811 For; 4,267,100 Against).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a report of the voting outcomes.
Investor Verification Checklist
- Verify the reason for the significant vote withholding against director nominee William D. Rueckert.
- Confirm the appointment of a replacement director for the term expiring in 2017 following the failure to elect William D. Rueckert.
- Review the definitive proxy statement for details on the executive compensation package approved in Proposal 3.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.